Table 1. Levels of immunoreactive Trx1 protein in human prostate tissuesa.
| Pathology | Number of specimens | Negative (−) |
Weak (+) |
Moderate (++) |
Strong (+++) |
|---|---|---|---|---|---|
| Benign epithelium | 48 | 0 | 27 (56%) |
16 (33%) |
5 (10%) |
| High grade prostatic intraepithelial neoplasia | 70 | 0 | 33 (47%) |
34 (49%) |
3 (4%) |
| Gleason pattern 2 | 2 | 0 | 1 (50%) |
1 (50%) |
0 |
| Gleason pattern 3 | 120 | 0 | 2 (2%) |
97 (81%) |
21 (18%) |
| Gleason pattern 4 | 40 | 0 | 2 (5%) |
14 (35%) |
24 (60%) |
| Metastatic cancer | 1 | 0 | 0 | 0 | 1 (100%) |
a
Semiquantification of immune-labeling intensity in tissue microarrays.
Immunohistochemical staining of Trx1 was semiquantitatively graded as negative (-), weak (+), moderate (++), or strong (+++) staining in at least 50% of cells examined. The relationship between the intensity of Trx1 staining, primarily in the nucleus, and prostate cancer stages were analyzed (p<0.01).